^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ASS1 negative

    i
    Other names: ASS1, Argininosuccinate synthase 1, Epididymis Secretory Sperm Binding Protein, Citrulline--Aspartate Ligase, Argininosuccinate Synthetase, ASS, CTLN1
    Entrez ID:
    445
    Related biomarkers:
    Expression
    Mutation
    1year
    Clinical Significance of Arginine Signaling in Patients with Cervical Cancer Receiving Cisplatin Chemoradiation Therapy. (PubMed, Int J Radiat Oncol Biol Phys)
    Overexpression of ASS1 is an independent prognostic factor for cervical cancer patients receiving cisplatin concurrent chemoradiotherapy.
    Journal
    |
    ASS1 (Argininosuccinate synthase 1)
    |
    ASS1 negative
    |
    cisplatin
    over1year
    Arginine metabolism key enzymes affect the prognosis of myelodysplastic syndrome by interfering with macrophage polarization. (PubMed, Cancer Med)
    Arginine metabolism may contribute to the prognosis of patients with MDS by affecting TAM polarization.
    Journal
    |
    ASS1 (Argininosuccinate synthase 1) • CD68 (CD68 Molecule) • NOS2 (Nitric Oxide Synthase 2)
    |
    ASS1 negative
    over1year
    Clinical Significance of Arginine Signaling in Patients with Cervical Cancer Receiving Cisplatin Chemoradiation Therapy (ASTRO 2023)
    Overexpression of ASS1 is an independent prognostic factor for cervical cancer patients receiving cisplatin concurrent chemoradiotherapy.
    Clinical
    |
    ASS1 (Argininosuccinate synthase 1)
    |
    ASS1 negative
    |
    cisplatin
    over1year
    A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma. (PubMed, Pharmacol Rep)
    Collectively, our data indicate that ADI-PEG20-inducible cytokines orchestrate argininosuccinate fuelling of ASS1-deficient mesothelioma by macrophages. This novel stromal-mediated resistance pathway may be leveraged to optimize arginine deprivation therapy for mesothelioma and related arginine-dependent cancers.
    Journal
    |
    ASS1 (Argininosuccinate synthase 1) • CXCR2 (Chemokine (C-X-C motif) receptor 2)
    |
    VEGFA elevation • ASS1 negative • VEGFA expression
    |
    Hepacid (pegargiminase) • clodronate disodium
    almost2years
    BAP1 loss is associated with higher ASS1 expression in epithelioid mesothelioma: implications for therapeutic stratification. (PubMed, Mol Cancer Res)
    Alterations in arginine metabolism may sensitise cells to metabolic drugs and we find that BAP1-negative/ASS1-expressing MPM cell lines are more sensitive to ASS1 inhibition, although not to inhibition of purine synthesis by mizoribine. Importantly, BAP1w-/KO MeT5A become desensitised to arginine-deprivation by pegylated arginine deiminase (ADI-PEG20), phenocopying BAP1-negative/ASS1-expressing MPM cell lines. Implications: Our data reveal an inter-relationship between BAP1 and arginine metabolism, providing a potential means of identifying epithelioid MPM patients likely to benefit from ADI-PEG20.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BAP1 (BRCA1 Associated Protein 1) • ASS1 (Argininosuccinate synthase 1)
    |
    BAP1 mutation • ASS1 negative • BAP1 negative
    |
    Bredinin (mizoribine) • Hepacid (pegargiminase)
    over2years
    A Phase 1 Study of ADI-PEG20 (Pegargiminase) Combined with Cisplatin and Pemetrexed in ASS1-Negative Metastatic Uveal Melanoma. (PubMed, Pigment Cell Melanoma Res)
    ADIPemCis was well tolerated with modest disease stabilisation in metastatic UM. Further investigation of arginine deprivation is indicated in UM including combinations with immune checkpoint blockade and additional antimetabolite strategies.
    P1 data • Journal • IO biomarker
    |
    ASS1 (Argininosuccinate synthase 1)
    |
    ASS1 negative
    |
    cisplatin • pemetrexed • Hepacid (pegargiminase)